IDiyas

For the Inventor, By the Inventor

Skillman, NJ, United States of America

David J Mathre

USPTO Granted Patents = 22 

Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 91(Granted Patents)


Location History:

  • Edison, NJ (US) (1988 - 1994)
  • Skillman,. both of, NJ (US) (1995)
  • Skillman, NJ (US) (1993 - 2000)

Company Filing History:

goldMedal22 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal1 out of 854 
 
Zeneca Limited
 patents
where one patent can have more than one assignee

Years Active: 1988-2000

Loading Chart...
22 patents (USPTO):
1. 6153787 - Intermediates for making heterocycles useful as COX-2 inhibitors (2000-11-28),
2. 5883267 - Process for making phenyl heterocycles useful as cox-2 inhibitors (1999-03-16),
3. 5777105 - Process for the preparation of imidazolyl macrolide immunosuppressants (1998-07-07),
4. 5773575 - Process for peptide segment condensation (1998-06-30),
5. 5760249 - Synthesis of hydroxysulfone and related compounds (1998-06-02),
6. 5693805 - Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists (1997-12-02),
7. 5688968 - Enantioselective synthesis of (1997-11-18),
8. 5686607 - Pyridyl ethylation of lactam derivatives (1997-11-11),
9. 5618934 - Boronic acid compound (1997-04-08),
10. 5594134 - Process of synthesizing N-acyl auxiliaries (1997-01-14),
11. 5574176 - Synthesis of an intermediate for the preparation of (1996-11-12),
12. 5461162 - Process of synthesizing n-acyl auxiliaries (1995-10-24),
13. 5369093 - Lipopeptide derivatives (1994-11-29),
14. 5336756 - Process for crystalline cyclic lipopeptides (1994-08-09),
15. 5264585 - Chiral catalysts for reduction of ketones and process for their (1993-11-23),

Title: David J. Mathre: Innovator in COX-2 Inhibition

Introduction

David J. Mathre, based in Skillman, NJ, is a notable inventor with a remarkable portfolio of 22 patents. With a focus on the development of compounds that serve as COX-2 inhibitors, his work has significant implications for the treatment of various diseases mediated by cyclooxygenase-2.

Latest Patents

Among Mathre's latest patents are two key inventions that revolve around the creation of intermediates for making heterocycles useful as COX-2 inhibitors. The first patent encompasses a process for synthesizing compounds of Formula I or Ia that are instrumental in treating cyclooxygenase-2 mediated diseases. Similarly, his second patent also details a process for manufacturing phenyl heterocycles with the same utility, underscoring his dedication to advancing pharmaceutical innovation.

Career Highlights

David has made impactful contributions during his career, having worked with renowned companies such as Merck & Company, Inc. and Zeneca Limited. His experience in these prestigious organizations has not only enhanced his expertise but has also allowed him to contribute to groundbreaking pharmaceutical research.

Collaborations

Throughout his career, Mathre has collaborated with talented peers, including Guo-Jie Ho and Paul Sohar. These partnerships have been pivotal in advancing their shared goals in developing effective COX-2 inhibitors.

Conclusion

In conclusion, David J. Mathre stands out as a significant figure in the field of medicinal chemistry. His innovative patents and collaborations reflect a profound dedication to addressing health challenges through scientific advancements. As the landscape of pharmaceuticals continues to evolve, Mathre's contributions will undoubtedly play a vital role in improving patient outcomes related to COX-2 mediated diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…